title: Prognostic value of non-MHC-restricted killer cell activity in lung cancer.
abstract: The prognostic value of peripheral blood non-MHC-restricted cytotoxicity against the myeloid leukaemic line K562 in lung cancer patients was studied. At the time of diagnosis and before operation, 57 patients with lung cancer were tested for cytotoxicity and subsequently followed for up to 4 years. In addition, 145 lung cancer patients, 30 patients with non-neoplastic lung diseases and 76 healthy donors were tested for cytotoxicity without the follow-up, in order to correlate the stage of lung cancer and the growth rate of tumours to the level of non-MHC-restricted cytotoxicity. On average, lung cancer patients had similar non-MHC-restricted cytotoxicity to the controls. However, patients with stage II-IV diseases showed an impaired activity, stages III and IV differing significantly from the controls. This result shows that the decline in natural killer (NK) activity is associated with tumour burden. Patients with slowly growing neoplasms had stronger cytotoxic activity than patients with fast or moderately progressing disease. In the follow-up study, the whole material of 57 patients showed only a slight correlation between cytotoxicity and survival: 42% of the patients with strong activity survived for more than 2.5 years, whereas 6% of the patients with weak activity did so. In stage I patients there was no correlation between cytotoxicity and survival, nor was there a correlation in patients with stages II-IV of the disease. Hence, in our group of patients the determination of cytotoxicity preoperatively yielded no prognostic information beyond that already available from staging. However, those stage II-IV patients that survived for 1 year or more after the diagnosis and cytotoxicity tests, showed a significant correlation between cytotoxicity and survival.
authors.affiliation: Institute of Cytology, St. Petersburg, Russia.
authors.forename: A M
authors.initials: AM
authors.lastname: Malygin
authors.forename: A A
authors.initials: AA
authors.lastname: Redjko
authors.forename: O N
authors.initials: ON
authors.lastname: Pogodina
authors.forename: N A
authors.initials: NA
authors.lastname: Karaseva
authors.forename: Y F
authors.initials: YF
authors.lastname: Koval
authors.forename: T
authors.initials: T
authors.lastname: Timonen
mesh_terms: D000368:Aged; D003601:Cytotoxicity Tests, Immunologic; D003602:Cytotoxicity, Immunologic / Q000276:immunology; D005260:Female; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology; D008175:Lung Neoplasms / Q000276:immunology* / Q000401:mortality* / Q000473:pathology; D008285:Major Histocompatibility Complex / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis